STARTVerso3: A randomized, double-blind, placebo-controlled phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection - Jacobson, I; Asselah, T; Ferenci, P (Hepatology, 2013)
et al.